Stock Pulse
Merck (MRK) secured a $493 million licensing deal with Cyprumed for an oral peptide delivery platform, potentially boosting growth [1]. Despite recent stock volatility and a "complete nightmare" period [2], Goldman Sachs reiterated a Buy rating, citing strong Animal Health performance [1]. Q4 2024 revenue exceeded expectations but full-year guidance fell short, leading to a stock decline [10]. Shareholder proposals and a general market downturn further contributed to negative sentiment [5]. While tariff concerns initially pressured the stock [4], [8], [9], the ultimate impact remains uncertain [7], [8]. The company's low price-to-earnings ratio suggests it may be undervalued [1], but concerns remain about future growth given weaker guidance and market pressures [10].